Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial - Wikidata - awgldk - TriplyDB

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

http://www.wikidata.org/entity/Q30505345

about

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer Current status of bevacizumab in advanced ovarian cancer Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

P2860

Q26751280-D250F8A9-0420-46DD-8AA0-F53CBA6CA0B4 Q35924450-B1ABB453-4319-4AC7-ACC6-E455508904C7 Q37022524-C26B6774-DE01-4610-8B78-D3405B472C49 Q37048186-DD789CC3-6BDD-4685-A905-AC1B0123FDE3 Q37435187-80582F28-7FD5-4EE9-87D0-A060A1AD335F Q39608246-9FA4B9D4-CEEE-4E8F-9BAB-049A0886D8C2

P2860

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

http://www.wikidata.org/entity/Q30505345

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@ast

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@en

type

label

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@ast

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@en

prefLabel

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@ast

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@en

P1433

Q30505345-00BE8E14-C300-4904-BA02-68E4F06CBC58

P1476

Q30505345-6D1C0A33-4D37-4FF1-B632-E6B9B8F974F1

P2093

Q30505345-1087C30C-7826-42FD-A10E-633D2587083C

Q30505345-56FD31F8-09BA-45D4-B591-449F005A99AE

Q30505345-573A1ECF-7C42-4C1E-A8CC-052DFBF9CA4A

Q30505345-8CADCF37-6D9B-484E-9F40-E09F06A9C8B1

Q30505345-A85EAAAF-E440-4256-9014-36AB9024D9A7

Q30505345-EA260122-52A8-4DBF-8CE6-60A37B76865E

P2860

Q30505345-042F694F-6773-46F7-8D49-66695611F780

Q30505345-0992DF73-E1A1-4D86-AC05-8485C180EAC4

Q30505345-2148EF08-2E32-451E-A5E0-65C1B4CB1261

Q30505345-37FDA067-8211-44BE-B280-3AC782049ABA

Q30505345-3C2E8CFA-5185-4F76-A05B-67B97DC3D3B9

Q30505345-3F6896B4-5836-459E-A977-F57B080E245D

Q30505345-5F71DE93-ADA4-4CBC-87B0-166E78FBE330

Q30505345-8CE51588-7F9F-423A-96F8-E10F13E8FBCF

Q30505345-933D899D-3314-43DD-9953-9279E87288B2

Q30505345-986731F3-5DF6-479C-9A3F-42D5267E1492

P304

Q30505345-3BAB6AA0-25A6-4ACB-B62E-E16B82DC1511

P31

Q30505345-DCBDEBAA-38EF-4787-A9FA-9FB5A836BBA9

P356

Q30505345-DC920FE2-8AF1-4A85-9DB8-2CF50CE86DAB

P407

Q30505345-D52E772B-22B1-40AC-A0C9-B387764E1782

P433

Q30505345-2E6DB5A1-EE58-4017-85A3-F008AAFCB6E3

P478

Q30505345-C7EF05FB-D364-4455-9157-A9BA7039581C

P577

Q30505345-D0A5FE81-BD1E-405F-9E71-E76A309E6718

P5875

Q30505345-9E52E8BC-F53A-46A9-BB2F-A971C2EDC678

P698

Q30505345-2BD867CD-F919-427D-AA7D-E65068ED5046

P921

Q30505345-1C0FD315-FCA1-4D3E-B78E-EA6247669EA0

Q30505345-654DEC6F-7EF5-45AC-B2F5-8921A640B3D5

Q30505345-C3BE5D40-9731-4FD5-BCAE-3585FE15F272

P932

Q30505345-ED4DB3B5-FC39-4B0E-A515-DE57C930E908

P356

J.YGYNO.2011.11.035

P1433

Gynecologic Oncology

P1476

Predictive value of serum CA-1 ...... Oncology Group phase II trial

@en

P2093

Barbara Buening

http://www.w3.org/2001/XMLSchema#string

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Joel I Sorosky

http://www.w3.org/2001/XMLSchema#string

Leslie M Randall

http://www.w3.org/2001/XMLSchema#string

Michael W Sill

http://www.w3.org/2001/XMLSchema#string

Robert A Burger

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study

Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.

On the relationship between response to treatment and survival time.

The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma.

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

P304

563-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2011.11.035

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51850420

http://www.w3.org/2001/XMLSchema#string

P698

22138229

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3278517

http://www.w3.org/2001/XMLSchema#string